GSA Capital Partners LLP Buys New Holdings in Iovance Biotherapeutics, Inc. $IOVA

GSA Capital Partners LLP acquired a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 655,318 shares of the biotechnology company’s stock, valued at approximately $2,726,000. GSA Capital Partners LLP owned about 0.15% of Iovance Biotherapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Xponance LLC grew its stake in Iovance Biotherapeutics by 19.4% during the fourth quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 3,950 shares in the last quarter. Raymond James Financial Inc. lifted its stake in Iovance Biotherapeutics by 1.4% in the 2nd quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 4,618 shares in the last quarter. Orion Investment Co boosted its holdings in shares of Iovance Biotherapeutics by 0.3% during the 4th quarter. Orion Investment Co now owns 1,856,934 shares of the biotechnology company’s stock valued at $5,069,000 after purchasing an additional 5,150 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Iovance Biotherapeutics by 37.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 19,290 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 5,301 shares during the last quarter. Finally, Captrust Financial Advisors grew its position in shares of Iovance Biotherapeutics by 13.5% during the fourth quarter. Captrust Financial Advisors now owns 46,812 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 5,563 shares in the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Analyst Ratings Changes

IOVA has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Chardan Capital dropped their price target on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Barclays raised their price target on Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Robert W. Baird set a $6.00 price objective on Iovance Biotherapeutics in a report on Friday, August 7th. Finally, Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a research report on Friday, August 7th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.00.

Iovance Biotherapeutics Trading Up 7.1%

Shares of NASDAQ IOVA opened at $6.98 on Friday. The firm’s 50-day moving average price is $4.65 and its 200-day moving average price is $3.94. The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of -9.56 and a beta of 0.71. Iovance Biotherapeutics, Inc. has a 12-month low of $1.76 and a 12-month high of $7.00.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The firm had revenue of $198.63 million during the quarter, compared to the consensus estimate of $87.83 million. During the same quarter last year, the firm earned ($0.33) EPS. The firm’s revenue for the quarter was up 65.7% compared to the same quarter last year. On average, equities analysts predict that Iovance Biotherapeutics, Inc. will post -0.5 EPS for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.